NASDAQ:NBP

Novabridge Biosciences Q4 2025 Earnings Results & Report

Novabridge Biosciences logo
$0.82 +0.03 (+3.89%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$0.84 +0.01 (+1.67%)
As of 07:31 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novabridge Biosciences reported Q4 2025 earnings on April 8, 2026. The company reported EPS of -$0.2990.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
After Market Closes

Novabridge Biosciences EPS Results

Actual EPS
-$0.2990
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Novabridge Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Novabridge Biosciences Q4 2025 Earnings FAQ

Novabridge Biosciences (NASDAQ:NBP) reported earnings of -$0.2990 per share for Q4 2025. The report was announced on Wednesday, April 8, 2026.

Novabridge Biosciences Earnings Headlines

Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.tc pixel
Brokers Offer Predictions for NBP FY2026 Earnings
See More Novabridge Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Novabridge Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novabridge Biosciences and other key companies, straight to your email.

About Novabridge Biosciences

Novabridge Biosciences (NASDAQ:NBP) (NASDAQ: NBP) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel biologic medicines, primarily for the treatment of cancer. Its research and development activities center on immunotherapies designed to activate the immune system or target specific proteins associated with tumor growth and survival.

The company’s pipeline has included investigational antibody-based therapies such as givastomig, a bispecific antibody designed to target Claudin 18.2 and stimulate an immune response through 4-1BB, as well as other programs directed at tumor-associated and immune-regulatory targets. These products remain in clinical development and are not necessarily approved for commercial use.

Novabridge Biosciences was founded in 2016 and historically maintained operations and development activities in both China and the United States. The company has since emphasized a more globally oriented, U.S.-focused development strategy while continuing to advance selected oncology programs through clinical studies and potential strategic partnerships. Dr. Joan Shen, a biopharmaceutical executive and physician, is the company’s founder and has served in senior leadership roles.

View Novabridge Biosciences Profile